Replies to post #322325 on Avid Bioservices Inc (CDMO)

[biopharm]

Anyone see the future of Avid Bioservices / MSK / Parker Instititue of Cancer Immunotherapy converging ?

Biological Processing to Reduce Drug Development Timelines and Bring Therapies to Market Faster

The Beacon Platform Combines Biology and Engineering to Shorten Biopharmaceutical Processes from Months to Days

....
.....
The digitization of biology coupled with increasing computational power and application of deep learning has paved the way for new and improved therapies. However, we need a way to deliver these therapies in a cost-effective and rapid manner and further increase access to all patients," said Michael Moritz, Partner, Sequoia Capital. "By combining the best of engineering with the world of biology, Berkeley Lights is helping companies achieve this with an automated platform that frees biologists from manual tasks to focus on discovering new treatments."

The integration of automation into the drug discovery workflow has the potential to reduce standard development timelines from 15 years to less than five years.1 Each day saved in the development of these therapies equates to reduced overall development costs and earlier patient access to vital drugs. Today Berkeley Lights' customers are using the Beacon platform to accelerate biological workflows, specifically for large molecule therapies.

The company is also applying its technology to diagnostics and cell therapy manufacturing for personalized medicine. Rapid advances in CAR-T, CRISPR based gene editing and other new discoveries enable human immune cell modification to combat cancer and show great promise. However, because these therapies use the patient's own immune cells, they are complex to discover, costly to manufacture and many patients go untreated.

"Berkeley Lights' technology gives scientists the ability to see, interact and automate biological processing to dramatically improve the speed and efficiency of research and development," said Eric Hobbs, PhD, CEO, Berkeley Lights. "Modern medicine is experiencing a biological revolution where new therapies that are able to combat complex disease are advancing rapidly. Our platforms provide the scale, speed, and cost efficiencies needed to accelerate these advances with the ultimate goal of providing access to life changing therapies for all patients."

...

...
https://www.prnewswire.com/news-releases/berkeley-lights-automates-biological-processing-to-reduce-drug-development-timelines-and-bring-therapies-to-market-faster-300517261.html

[biopharm]

Who is the Quartz Bio CEO and Founder from Sept 2012 - Oct 2017 ?
https://www.linkedin.com/in/jeromewojcik

....
Now he works for PMG along with Tobias Guennel...etc

Does everyone see the light? I hope so...because there is no way all these control arm issues occur and Peregrine playing musical chairs with Ronin Hedge Group it seems and do they even dare try a breadcrumbs deal ? I certainly hope not...because I see the light clearly

Berkeley Lights even and John R. Gunn 30 years at Memorial Sloan Kettering ?? We can't make this up ...of course Mr. Gunn has got to talk with Dr Jedd Wolchok.....one would assume.

https://www.berkeleylights.com/our-story/leadership/

How many non disclosed collaborations have existed that the new BODs are not aware about or maybe I should say how many have opportunities are being advanced in other areas or other companies that have had peeks into leaks of the platformitude (new word = astronomical amounts of data, generally Biomarker data, that is taken from one collaboration and used to profit another collaboration without expressed rights back to original IP owner) of information derived out of Peregrine Pharmaceuticals collaborations.

Has anyone wondered if the info matches up that was available to the old BOD vs the new....? FDA records can be summoned by the new BODs to make sure every piece of data the FDA has been provided is also provided to the new BODs....

This is all about proactive measures so the new BODs are not able to say "they did not know...a,b,c....to z" and any breadcrumbs deal must not be finalized till sharehders are provided with enough guarantees that fiduciary Duties are followed 100%

What is their rush anyhow to divest anything ....if it is true that the IP is not that worthy lol

Wake up and send in certified letters today, next day express

Make mention of many things in the last dozen posts because obviously, this is quiet time for the big deal or they are in on this staged act with what looks like some cover story to assist in the transfer of the IP